| HSY |
Report |
Q2 adjusted EPS |
BEAT |
pred ~$1.48 vs. cons $1.43 |
MEDIUM |
| HSY |
Report |
Q2 net sales |
IN-LINE |
pred ~$2.64B vs. cons $2.634B |
MEDIUM |
| HSY |
Report |
Q2 adjusted gross margin |
IN-LINE |
pred ~41.4% vs. cons 41.0% |
MEDIUM |
| HSY |
Guide |
Adjusted EPS |
LOWER |
guide ~$8.45 vs. cons $8.48 (FY2026) |
MEDIUM |
| HSY |
Guide |
Reported net sales growth |
UNCHANGED |
guide ~4.75% vs. cons 4.73% (FY2026) |
MEDIUM |
| HSY |
Guide |
Adjusted EPS growth commentary |
LOWER |
guide ~15.0% vs. cons 16.7% (FY2027) |
LOW |
| HSY |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.2% |
— |
MEDIUM |
| HSY |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
A modest Q2 EPS beat is outweighed by an FY2026 guide midpoint below consensus and FY2027 commentary that does not validate the full Street recovery. Using predicted H1 adjusted EPS of ~$3.83, the ~$8.45 FY2026 guide implies ~$4.62 for H2 versus consensus near $4.67, prompting modest out-period estimate cuts after the initial reaction. |
MEDIUM |